X T L Biopharmaceuticals التزامات 2024

ماذا تفعل X T L Biopharmaceuticals؟

XL Biopharmaceuticals was founded in 2000 as a biotech company with headquarters in France. The company aims to enter the market for biological agents. It focuses on the research, development, and manufacturing of therapeutic antibodies, known as monoclonal antibodies. These are specific immunological proteins that can selectively attack and eliminate disease-causing molecules in the body. Monoclonal antibodies have a wide range of applications in therapy, including the treatment of cancer, rheumatic diseases, and autoimmune diseases. XL Biopharmaceuticals' business model is based on a strategic three-part approach. Firstly, it provides contract research and development services for other biotech and pharmaceutical companies. Secondly, it develops its own products for therapeutic applications, specializing in antibodies for oncology, particularly for the treatment of solid tumors. Lastly, it operates a drug development platform for neurological diseases such as Parkinson's and Alzheimer's, focusing on monoclonal antibodies targeting specific targets. One of XL Biopharmaceuticals' key products is the antibody BXL101, currently being tested in a phase II clinical trial for the treatment of breast cancer. BXL101 targets a surface protein that is elevated in many breast cancer patients. Another product under development is BXL0124, a monoclonal antibody for the therapy of Alzheimer's. This targets an abnormal aggregation of a protein called Tau in the brain cells of Alzheimer's patients. XL Biopharmaceuticals employs approximately 45 people and has filed over 90 patents since its founding. The company is funded by private investors and public grants from various sources, including the European Union. Answer: XL Biopharmaceuticals is a French biotech company specializing in the research, development, and manufacturing of therapeutic antibodies. They offer contract research and development services, develop their own products for therapeutic applications, and have a drug development platform for neurological diseases. The company's key products include BXL101 for breast cancer and BXL0124 for Alzheimer's. They have filed over 90 patents and are funded by private investors and public grants. X T L Biopharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.